CStone Revs Up For Big Growth With New Drug Approval

Jan. 03, 2022 7:29 AM ETCStone Pharmaceuticals (CSPHF)PFE2 Comments
Bamboo Works profile picture
Bamboo Works


  • CStone announced its monoclonal antibody drug Cejemly has been approved by China’s drug regulator for the treatment of certain lung cancers.
  • The company is valued relatively low compared with its peers and is expected by Morgan Stanley to turn a profit in 2023.
  • CStone fell below its IPO price of HK$12 in September.

Abstract nano molecular structure

MF3d/E+ via Getty Images

Biomedical company CStone Pharmaceuticals (OTCPK:CSPHF) has been cleared in China to sell its first cancer drug, which it is commercializing with the global pharmaceutical giant Pfizer (PFE), marking an important step for its

This article was written by

Bamboo Works profile picture
Profit on the recent rally for Chinese stocks at Bamboo Works(www.thebambooworks.com), the premium source for news about US-listed Chinese companies.Bamboo Works provides news on Chinese companies listed in the United States and Hong Kong, with a strong focus on mid-cap and also pre-IPO companies. Contact us at info@thebambooworks.com to learn about opportunities for sponsored content.

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.